| Autor: |
Chiarito, Mauro, Sardella, Gennaro, Colombo, Antonio, Briguori, Carlo, Testa, Luca, Bedogni, Francesco, Fabbiocchi, Franco, Paggi, Anita, Palloshi, Altin, Tamburino, Corrado, Margonato, Alberto, Pivato, Carlo Andrea, Baber, Usman, Calcagno, Simone, Giordano, Arturo, Godino, Cosmo, Stefanini, Giulio G. |
| Přispěvatelé: |
Chiarito, Mauro, Sardella, Gennaro, Colombo, Antonio, Briguori, Carlo, Testa, Luca, Bedogni, Francesco, Fabbiocchi, Franco, Paggi, Anita, Palloshi, Altin, Tamburino, Corrado, Margonato, Alberto, Pivato, Carlo Andrea, Baber, Usman, Calcagno, Simone, Giordano, Arturo, Godino, Cosmo, Stefanini, Giulio G. |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Popis: |
Background Polymer-free drug-eluting stents are based on different technologies for drug binding and release without the use of polymer coatings. It is unknown whether different polymer-free drug-eluting stents are comparable in terms of safety and efficacy profiles. Methods and Results Polymer-free BioFreedom biolimus-eluting stents (BES) and polymer-free Cre8 amphilimus-eluting stents (AES) were investigated in 2 recent multicenter registries including 2320 all-comer patients undergoing percutaneous coronary interventions at 22 Italian centers. Using propensity score matching, safety and efficacy outcomes were compared among 1280 patients (640 matched pairs) treated with BioFreedom BES or Cre8 AES. The primary end point was target lesion failure-a composite of cardiac death, target vessel myocardial infarction, and target lesion revascularization (TLR). At 1 year, target lesion failure occurred in 4.0% of BES and 4.2% of AES-treated patients (hazard ratio [HR] 0.98, 95% CI, 0.57-1.70). Risks of cardiac death (2.0% versus 2.1%; HR, 1.03; 95% CI, 0.47-2.26), target vessel myocardial infarction (0.8% versus 0.3%; HR, 1.89; 95% CI, 0.50-6.80), TLR (1.5% versus 2.2%; HR, 0.74; 95% CI, 0.34-1.62), and definite/probable stent thrombosis (0.9% versus 0.8%; HR, 1.17; 95% CI, 0.36-3.81) were comparable in patients treated with BioFreedom BES and Cre8 AES. A differential treatment effect by diabetes mellitus status was observed, indicating a benefit of AES in patients with diabetes mellitus ( P interaction=0.003). Conclusions The present study shows that BioFreedom BES and Cre8 AES have favorable and comparable safety and efficacy profiles in all-comer patients undergoing percutaneous coronary intervention. Further evaluation in large-scale, randomized trials are necessary to confirm our findings. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
